|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1989-12-18
|
|
pubmed:abstractText |
Sixty previously untreated patients with high grade non-Hodgkin's lymphomas stages II-IV received cyclophosphamide 750 mg m2 i.v., doxorubicin 50 mg m2 i.v., and vincristine 2 mg i.v. on day 1, prednisolone 100 mg p.o. on days 1-5 and etoposide 100 mg m2 i.v. on days 3-5 (CHOP-VP16). After four courses an involved field irradiation with a total dose of 25 Gy was employed and followed by two additional courses of CHOP-VP16. The overall response rate was 93%, with 49 patients (82%) achieving a complete remission (CR). Seven patients had a partial response and four patients showed no response. During a median follow-up period of 55 months, 22 of the 49 patients with CR relapsed, seven of them achieving a second complete remission with the same drug regimen. A maintained complete remission of up to 68 months was seen in 55% of all patients initially achieving CR. The median survival is 43 months. Mean side-effects of this drug regimen were alopecia (89%), nausea/vomiting (76%) and leukopenia (61%). No therapy-related deaths were seen. The results of this study demonstrate that this combined modality treatment produces high complete remission rates and that more than half of these patients achieve long-term disease-free survival.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-2418166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-2579725,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-2580468,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-3531069,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-3772416,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-6173118,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-6179448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-6187213,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-6600902,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-6993438,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-7083457,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679846-791473
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
79-82
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2679846-Adolescent,
pubmed-meshheading:2679846-Adult,
pubmed-meshheading:2679846-Aged,
pubmed-meshheading:2679846-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2679846-Combined Modality Therapy,
pubmed-meshheading:2679846-Cyclophosphamide,
pubmed-meshheading:2679846-Doxorubicin,
pubmed-meshheading:2679846-Drug Evaluation,
pubmed-meshheading:2679846-Etoposide,
pubmed-meshheading:2679846-Female,
pubmed-meshheading:2679846-Germany, West,
pubmed-meshheading:2679846-Humans,
pubmed-meshheading:2679846-Lymphoma, Non-Hodgkin,
pubmed-meshheading:2679846-Male,
pubmed-meshheading:2679846-Middle Aged,
pubmed-meshheading:2679846-Multicenter Studies as Topic,
pubmed-meshheading:2679846-Prednisolone,
pubmed-meshheading:2679846-Prednisone,
pubmed-meshheading:2679846-Survival Rate,
pubmed-meshheading:2679846-Vincristine
|
|
pubmed:year |
1989
|
|
pubmed:articleTitle |
CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.
|
|
pubmed:affiliation |
Department of Internal Medicine, Philipps-University, Marburg, Federal Republic of Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
